Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–86 of 86 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cladribine Clear all
Not yet recruiting Phase 1Phase 2 Interventional

A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)

NCT07053020
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Cytarabine, Oral Cladribine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 17, 2026, 5:13 AM EDT
Active, not recruiting Phase 4 Interventional

Cladribine Tablets After Treatment With Natalizumab (CLADRINA)

NCT04178005
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cladribine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Overland Park, Kansas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 17, 2026, 5:13 AM EDT
Recruiting Phase 2 Interventional

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

NCT01515527
View directory record Official record
Conditions
Leukemia
Interventions
Cladribine, Cytarabine, Decitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 17, 2026, 5:13 AM EDT
Completed Phase 2 Interventional

Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia

NCT00003178
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, cladribine, idarubicin
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
206
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 17, 2026, 5:13 AM EDT
Completed Phase 2 Interventional

Cladribine in Patients With Mantle Cell Lymphoma

NCT00002879
View directory record Official record
Conditions
Lymphoma
Interventions
cladribine
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2008
U.S. locations
20
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 17, 2026, 5:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm

NCT03531918
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Cladribine, Cytarabine, Gemtuzumab Ozogamicin, Recombinant Granulocyte Colony-Stimulating Factor, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride
Drug · Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 17, 2026, 5:13 AM EDT
Recruiting Phase 2 Interventional

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

NCT02115295
View directory record Official record
Conditions
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Blasts 10 Percent or More of Peripheral Blood White Cells, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
Cladribine, Cytarabine, Gilteritinib, Idarubicin, Laboratory Biomarker Analysis, Midostaurin, Venetoclax
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 17, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

NCT02756572
View directory record Official record
Conditions
Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2, High Grade Malignant Neoplasm, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts-2, Myeloid Neoplasm, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Cladribine, Cyclosporine, Cytarabine, Filgrastim, Fludarabine Phosphate, Allogeneic Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Melphalan, Mitoxantrone Hydrochloride, Mycophenolate Mofetil, Questionnaire Administration, Sirolimus, Total-Body Irradiation, Melphalan Hydrochloride
Drug · Biological · Procedure + 2 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 17, 2026, 5:13 AM EDT
Completed Phase 4 Interventional Results available

Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)

NCT03961204
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Data Collection
Other
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 17, 2026, 5:13 AM EDT
Completed No phase listed Observational Results available

A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)

NCT03933202
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cladribine Tablets
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
66
States / cities
Cullman, Alabama • Mobile, Alabama • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 17, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

NCT04195945
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myeloid Neoplasm
Interventions
Liposome-encapsulated Daunorubicin-Cytarabine, Cladribine, Cytarabine, Recombinant Granulocyte Colony-Stimulating Factor, Mitoxantrone, Questionnaire Administration, Quality-of-Life Assessment
Drug · Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 17, 2026, 5:13 AM EDT
Completed Phase 4 Interventional Results available

Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis

NCT03963375
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Cladribine
Drug
Lead sponsor
Gregory Wu
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
5
States / cities
St Louis, Missouri • Oklahoma City, Oklahoma • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 17, 2026, 5:13 AM EDT
Active, not recruiting Phase 4 Interventional

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

NCT03535298
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Early Highly Effective Therapies Group, Escalation Therapies Group
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Aurora, Colorado • Minneapolis, Minnesota • Rochester, Minnesota + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 17, 2026, 5:13 AM EDT
Completed Phase 1 Interventional

Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab

NCT00667329
View directory record Official record
Conditions
Lymphoma
Interventions
2CdA, Cyclophosphamide, Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 17, 2026, 5:13 AM EDT